^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

986P - Response to capmatinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) and MET exon 14 skipping (METex14) mutation: Whole transcriptome analysis from phase II GEOMETRY Mono-1 study

Published date:
09/05/2022
Excerpt:
Pts with advanced METex14 NSCLC received oral capmatinib 400 mg twice daily….1L pts with high MET expression had significantly longer PFS than 1L pts with low MET expression (p<0.01, Cox model).